NCCN
Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests
The newest version ups its endorsement of somatic genomic testing to "recommended" for advanced cancers and shifts its recommendations on early-stage risk assays.
NCCN Adds Prostate Cancer to Genetic Risk Assessment Guidelines
The NCCN also recently updated genetic risk guidelines for colorectal, endometrial, and gastric cancers.
NCCN Calls ctDNA Emerging Colon Cancer Prognostic Marker, Does Not Back Use Outside Clinical Trials
The panel noted limited data on whether recurrence risk scores from ctDNA testing or multigene assays predict chemotherapy benefit among colon cancer patients.
Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test
The genomic test is covered by Medicare for all men with localized prostate cancer being considered for treatment.